An investigation on behalf of investors in Eidos Therapeutics, Inc. (NASDAQ: EIDX) shares over potential wrongdoing at Eidos Therapeutics, Inc was announced and NASDAQ: EIDX stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 05/29/2019 -- Certain directors of Eidos Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.
Investors who purchased shares of Eidos Therapeutics, Inc. (NASDAQ: EIDX) and currently hold any of those NASDAQ: EIDX shares have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Eidos Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Francisco, CA based Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). On April 1, 2019, after the market closed, Eidos Therapeutics, Inc filed a Form with the Securities and Exchange Commission ("SEC") announcing that its previously issued financial statements for the first three quarterly periods in the year ended December 31, 2018 could no longer be relied upon.
Those who purchased shares of Eidos Therapeutics, Inc. (NASDAQ: EIDX) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels